Geron (GERN) Operating Income (2010 - 2026)
Geron's (GERN) quarterly Operating Income came in at -$12.5 million in Q2 2026, little changed year-over-year from -$12.5 million in Q2 2025, and down 8008.86% quarter-over-quarter from $158000.0 in Q1 2026.
Analysis
Geron (GERN) Operating Income (2010 - 2026) Analysis & Trends
Geron has disclosed Operating Income across 17 years of filings, most recently posting -$12.5 million for Q2 2026.
- In Q2 2026, Operating Income changed 0.34% year-over-year to -$12.5 million; the TTM figure through Jun 2026 stood at -$51.8 million (up 33.14% YoY), while the FY2025 annual figure was -$68.6 million, up 60.52% from the prior year.
- Operating Income came in at -$12.5 million for Q2 2026 at Geron, down from $158000.0 in the prior quarter.
- In the past five years, Operating Income ranged from a high of $158000.0 in Q1 2026 to a low of -$69.3 million in Q2 2024.
- Average Operating Income over 5 years is -$32.6 million, with a median of -$28.4 million recorded in 2022.
- Year-over-year, Operating Income plunged 85.7% in 2023 and jumped 100.95% in 2026.
- Over 5 years, Operating Income stood at -$42.0 million in 2022, then dropped by 29.41% to -$54.3 million in 2023, then surged by 63.07% to -$20.0 million in 2024, then declined by 27.38% to -$25.5 million in 2025, then jumped by 51.07% to -$12.5 million in 2026.
- Per Business Quant data, the three most recent Operating Income figures were -$12.5 million in Q2 2026, $158000.0 in Q1 2026, and -$25.5 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 3.51 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -10.39 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.29 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 493.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -815.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -644.50 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -365.99 Mn |
| 10 | Geron | 914.60 Mn | 613.75 Mn | - | -12.50 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -12.50 Mn |
| Mar 31, 2026 | 158,000.00 |
| Dec 31, 2025 | -25.54 Mn |
| Sep 30, 2025 | -13.89 Mn |
| Jun 30, 2025 | -12.45 Mn |
| Mar 31, 2025 | -16.70 Mn |
| Dec 31, 2024 | -20.05 Mn |
| Sep 30, 2024 | -28.22 Mn |
| Jun 30, 2024 | -69.33 Mn |
| Mar 31, 2024 | -56.13 Mn |
| Dec 31, 2023 | -54.29 Mn |
| Sep 30, 2023 | -47.61 Mn |
| Jun 30, 2023 | -51.95 Mn |
| Mar 31, 2023 | -40.09 Mn |
| Dec 31, 2022 | -41.95 Mn |
| Sep 30, 2022 | -39.95 Mn |
| Jun 30, 2022 | -27.98 Mn |
| Mar 31, 2022 | -28.68 Mn |
| Dec 31, 2021 | -30.98 Mn |
| Sep 30, 2021 | -25.67 Mn |